SLC5A2 and urinary tract infection: Sodium-glucose Cotransporter 2 inhibitor medications (SGLT2 inhibitors), which promote glucosuria, are known to raise the risk of urinary tract infection and candidiasis, risks that may be unacceptable in an immunocompromised population.